Menu
← Oncology Approval Tracker
FDA DECISION ·
Ojjaara
momelotinib · GlaxoSmithKline
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with anemia and intermediate- or high-risk myelofibrosis, including primary disease and disease arising after polycythemia vera or essential thrombocythemia.
LAMPGEN ANALYSIS
Why it matters
The decision added a targeted option specifically for anemic patients with intermediate- or high-risk myelofibrosis.
What research teams should watch
Document risk category, baseline anemia and transfusion history alongside spleen and symptom assessments.
PRIMARY RECORDS